The Emerging Role of Immunotherapy in Hodgkin Lymphoma

Access Course



Drs Ansell, Armand, and Diefenbach discuss the latest research into the use of checkpoint inhibition in Hodgkin lymphoma.


This activity is intended for hematologists, pathologists, and other healthcare professionals who treat patients with Hodgkin lymphoma.The goal of this activity is to discuss the recent advances in the use of immunotherapy for Hodgkin lymphoma.





Approximate Time to Complete: 30 minutes


Credit Available: Nov. 14, 2017 - Nov. 14, 2018


Developed through a partnership between SITC and Medscape.

sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
Course Objectives
Upon completion of this activity, participants will be able to:
  • Have increased knowledge regarding the role of immune escape in the development of Hodgkin lymphoma (HL)
  • Have increased knowledge regarding the clinical data on the efficacy of immunotherapy for the treatment of Hodgkin lymphoma
  • Have greater competence related to their ability to manage side effects associated with checkpoint inhibitor therapy
Accreditation Council For Continuing Medical Education
AMA PRA Category 1 Credit(s)™: 0.50
American Board of Internal Medicine
ABIM MOC Part 2 Credits: 0.50
American Nurses Credentialing Center's Commission on Accreditation
Contact Hour: 0.50